Alphatec Holdings faces investor investigation following revenue guidance cut

Shares of Alphatec Holdings declined sharply in late October after the company reduced its full-year 2026 revenue guidance to approximately $862 million. This move marked a significant departure from earlier projections, falling $20 million short of the previously stated $882 million goal.

Management cited three primary operational headwinds for the revision: lower-than-anticipated biologics attachment rates, reduced volumes in thoracolumbar procedures, and temporary constraints within international supply chains. This guidance cut follows an earlier downward adjustment made by the company after the first quarter of 2026.

In response to the share price volatility, the law firm SueWallSt—operating under Levi & Korsinsky LLP—has initiated an investigation into whether the company violated securities laws. The investigation seeks to determine if shareholders were misled regarding the firm's operational stability or future financial performance.

Investors who incurred losses as a result of the guidance shift are currently being solicited for a confidential review. The firm, which specializes in shareholder litigation, stated that there is no deadline for submitting documentation and that cases of this nature are typically handled on a contingency basis.